Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 1/2 7Phase 1 7Phase 3 4Phase 2/3 2Phase 4 1

Status

Completed 4Terminated 2Recruiting 1

Sponsor Class

INDUSTRY 7OTHER 3NIH 1

Study Type

Interventional 7

Sponsor

Cancer Type

Tumor-Agnostic 2Dermatologic 2Thoracic 1Other solid neoplasm 1Head & Neck 1Genitourinary 1Gastrointestinal 1

Conditions

Neoplasms 2Uveal Melanoma 1Squamous Cell Carcinoma of Head and Neck 1Melanoma 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Advanced Solid Tumors 1Advanced Cancer 1

Interventions

pembrolizumab 304Paclitaxel 206Carboplatin 200Gemcitabine 173Cisplatin 139Docetaxel 138Cyclophosphamide 136Nivolumab 129Bevacizumab 118Injections 111fludarabine 96atezolizumab 91Pemetrexed 90Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 71Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Lenalidomide 55Ipilimumab 55Midazolam 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × relatlimab × Clear all
NCT05176483 2026-05-27

STELLAR-002

Exelixis

Phase 1 Recruiting
1,314 enrolled
GastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Colorectal Neoplasms

NCT04935229 2025-10-22

Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma

TriSalus Life Sciences, Inc.

Phase 1 Terminated
67 enrolled
Dermatologic

Uveal Melanoma

NCT02966548 2025-02-17

Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid Tumors

Bristol-Myers Squibb

Phase 1 Completed
35 enrolled
Tumor-Agnostic

Neoplasms

NCT03978611 2024-07-24

A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment

Bristol-Myers Squibb

Phase 1 Terminated
11 enrolled
Dermatologic

Melanoma

NCT05498480 2024-02-20

RELATIVITY-111

Bristol-Myers Squibb

Phase 1 Completed
6 enrolled
Other solid neoplasm

Advanced Solid Tumors

NCT04112498 2023-04-06

A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab

Bristol-Myers Squibb

Phase 1 Completed
24 enrolled
Tumor-Agnostic

Neoplasms

NCT03335540 2022-09-26

ADVISE

Bristol-Myers Squibb

Phase 1 Completed
20 enrolled

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡